5AA Limited Human
Ipamorelin
Selective synthetic pentapeptide that triggers pulsatile growth hormone release from the pituitary without elevating stress hormones.
In Plain English: Ipamorelin is a small five-amino-acid peptide that acts like a key fitting the body's growth hormone 'lock' — the ghrelin receptor in the pituitary gland — prompting a natural burst of GH secretion. Unlike older GH-stimulating peptides, it does so without raising cortisol or ACTH, making it notably cleaner in its hormonal profile.
Research Maturity
Limited Human (~50 PubMed publications; 1 Phase 2 RCT (n=117), 2 human PK studies, rest animal+ Studies)
Quick Facts
Focus
Body Composition
Bone & Metabolic Health
Hormone Signaling
Route
IV
SubQ
Origin
Fully synthetic pentapeptide developed by Novo Nordisk in the late 1990s (coded NNC 26-0161), derived by structural optimisation of GHRP-1. Sequence engineered to maximise GHS-R1a selectivity.
Mechanism
Selective agonist of GHSR-1a. Binding triggers intracellular calcium mobilisation and PKC-dependent signalling, releasing discrete GH pulses. Does not displace cortisol or ACTH at 200x supratherapeutic doses. Leaves FSH, LH, PRL, and TSH unaffected.
Outcome
Peak serum GH and AUC, serum IGF-1, longitudinal bone growth rate, periosteal bone formation rate, gastric emptying time, body composition, cortisol/ACTH confirmation of selectivity.
Safety Flags & Warnings
Transient GH-Related Side Effects
No Cortisol/ACTH Elevation
Monitor Blood Glucose
Always consult a licensed physician. Research purposes only.
€5.3 / mg
